osimertinib
astrazeneca
['sclc', 'nsclc', 'osimertinib']
phase ii trial of neoadjuvant #osimertinib for resectable egfr-mutant nsclc by . n=27. mpr (primary endpoint) = 15%, did not meet the primary endpoint. no pcr. disease persistence is a key issue to address. important translational insights generated. #asco2023 
Thoracic Medical Oncologist at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM